Результаты поиска

Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma.

BackgroundDasatinib is an oral inhibitor of the Src kinase family, with preclinical data indicating impact on gliomagenesis, tumor invasion, and radiosensitivity.MethodsNorth Central Cancer Treatment Group N0877 is a phase 1 dose escalation and phase II randomized study evaluating the maximum tolerated dose (MTD), safety, and efficacy of dasatinib with radiation and temozolomide (TMZ) for glioblastoma. Following identification of the MTD, adult patients with a histologic diagnosis of glioblastoma were randomized 2:1 between dasatinib given with standard concurrent and adjuvant TMZ, versus plac

Совпадение в полном тексте источника
… Duffy; Iowa-Wide Oncology Research Coalition NCORP, Des Moines, IA; Joshua Lukenbill; UG1CA189816; John B Amos Cancer Center, Columbus, GA; Andrew W. Pippas; Mayo Clinic LAPS, Rochester, MN; Steven R. … Mowat; University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA; Chandrikha Chandrasekharan; Wake Forest University Health Sciences, Winston-Salem, NC; Heidi Diana Klepin; Washington University - Siteman Cancer Center LAPS, Saint Louis, MO; Nancy L. …